May 11, 2021
Business News

Shorla Pharma Announces FDA Filing Acceptance and Priority Review for T-cell Leukemia Treatment

CLONMEL, Ireland–()–Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced today that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a lifesaving treatment that is often in shortage and the company looks forward to working closely with FDA to bring this much needed product to market later this year.

“We’re very proud that SH-111 will have a significant clinical benefit particularly for children with leukemia,” said Sharon Cunningham, CEO and Co-founder of Shorla Pharma. “It’s a desperately needed product and a life-changing treatment…

Click here to view the original article.

Related Posts

You might also like ...

XL Fleet Confirms Changes to Warrant Accounting Treatment Following SEC Statement
AON Splash Image
CIBC Innovation Banking provides Vertu Capital with a Capital Call Line of Credit
FINBOA Celebrates First Quarter Growth